皮肤肌炎治疗的过去,现在和未来
Melody P Chung1, Julie J Paik1
1Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Current treatment options in rheumatology
|April 23, 2024
概括
本综述总结了针对皮肤肌炎 (DM) 的新兴药理疗法. 最近的进展包括FDA批准的IVIg和正在进行的JAK抑制剂,T细胞抑制剂和其他新型治疗方法的试验,扩大DM患者的治疗选择.
科学领域:
- 类风湿病学 类风湿病学
- 皮肤病学 皮肤病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 皮质神经炎 (DM) 是一种罕见的自身免疫性疾病,需要有效的治疗选择.
- 目前DM的治疗策略正在随着新的研究而发展.
研究的目的:
- 审查当前和新兴的药理疗法治疗皮肤肌炎.
- 总结DM治疗的临床证据和正在进行的试验.
主要方法:
- 对当前临床证据的文献综述.
- 最近发表的和正在进行的DM药物临床试验的摘要.
主要成果:
- 美国食品和药物管理局批准了Octagam® 10% 免疫球蛋白静脉注射 (IVIg) 用于DM治疗.
- 雅克抑制剂 (托法西提尼布,巴里西提尼布) 和阿巴切是2/3期试验的关键标.
- 试验正在探索新的途径:免疫蛋白酶体抑制剂,抗B细胞疗法,抗干扰素,补充抑制剂和PDE4抑制剂.
结论:
- 在DM治疗研究中显著的进展是显而易见的.
- 糖尿病治疗领域正在迅速发展,许多新型疗法正在开发中.
- 改进的分类和结果措施将有助于未来的治疗策略.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
160
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
160
Myasthenia Gravis: Overview and Treatment
1.4K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.4K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
134
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
134
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
116
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
116
The JAK-STAT Signaling Pathway
8.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.8K


